Compare VSH & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSH | DYN |
|---|---|---|
| Founded | 1962 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.8B |
| IPO Year | 1994 | 2020 |
| Metric | VSH | DYN |
|---|---|---|
| Price | $35.07 | $25.70 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $18.00 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 4.8M | 2.5M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 69.57 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $3,069,048,000.00 | N/A |
| Revenue This Year | $12.58 | N/A |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | $133.30 | ★ N/A |
| Revenue Growth | ★ 4.48 | N/A |
| 52 Week Low | $11.77 | $11.65 |
| 52 Week High | $69.47 | $27.31 |
| Indicator | VSH | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 56.28 |
| Support Level | $33.36 | $16.55 |
| Resistance Level | $40.70 | $26.62 |
| Average True Range (ATR) | 2.73 | 1.15 |
| MACD | 0.49 | -0.16 |
| Stochastic Oscillator | 54.54 | 49.18 |
Vishay Intertechnology Inc provides a broad product portfolio of discrete semiconductors and passive electronic components to original equipment manufacturers and distributors. These products are found in industrial, computing, automotive, consumer, telecommunications, power supplies, military, aerospace, and medical markets and serve customer all over the world. Its product segments consist of two general classes: semiconductors and passive components. The company's operating segment includes metal oxide semiconductor field-effect transistors, diodes, optoelectronic components, resistors, inductors, and capacitors. Revenue mainly comes from resistors, which are basic components used in all forms of electronic circuitry to adjust and regulate levels of voltage and current.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.